Home
HelpTest Code LAB1234679 BCR::ABL1, Qualitative, Diagnostic Assay, Varies
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Reporting Name
BCR/ABL1, RNA-Qual, DiagnosticSpecimen Type
VariesOrdering Guidance
This test is qualitative only and should not be used for routine therapeutic measurable residual disease monitoring.
To monitor patients carrying BCR::ABL1 fusion forms coding for p190 (e1a2), order BA190 / BCR::ABL1, p190 mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies.
To monitor patients carrying BCR::ABL1 fusion forms coding for p210 (e13/e14a2) protein, order BCRAB / BCR::ABL1, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myeloid Leukemia (CML), Varies.
To monitor patients carrying rare BCR::ABL1 fusion forms coding for e19a2, e13/e14a3, e1a3, e6a2, e19a3, e8a2, e12a2, e6a3, e8a3, and e12a3, order BARQ / BCR::ABL1, Rare Fusion Monitoring, Quantitative, Varies.
Shipping Instructions
Refrigerate specimens must arrive within 5 days of collection, and ambient specimens must arrive within 72 hours of collection. Collect and package specimens as close to shipping time as possible.
Necessary Information
Pertinent clinical history including the patient diagnosis of chronic myelogenous leukemia or other BCR::ABL1-positive neoplasm is required.
Specimen Required
Submit only 1 of the following specimens:
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Yellow top (ACD)
Specimen Volume: 10 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
3. Label specimen as whole blood.
Specimen Type: Bone marrow
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Yellow top (ACD)
Specimen Volume: 4 mL
Collection Instructions:
1. Invert several times to mix bone marrow.
2. Send bone marrow specimen in original tube. Do not aliquot.
3. Label specimen as bone marrow.
Reject Due To
| Gross hemolysis | Reject |
| Moderately to severely clotted | Reject |
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Varies | Refrigerated (preferred) | 5 days | PURPLE OR PINK TOP/EDTA |
| Ambient | 72 hours | PURPLE OR PINK TOP/EDTA |
Specimen Minimum Volume
Whole blood: 8 mL; Bone marrow: 2 mL
Special Instructions
Day(s) Performed
Monday through Saturday
Specimen Retention Time
Whole blood/Bone marrow: 2 weeks; Extracted RNA: 3 monthsReport Available
5 to 10 daysReference Values
A qualitative result is provided that indicates the presence or absence of BCR::ABL1 messenger RNA. When positive, the fusion variant is also reported.
Useful For
Initial diagnosis of BCR::ABL1-positive hematologic neoplasms (eg, chronic myeloid leukemia and acute lymphoblastic leukemia)
Detection and identification of BCR::ABL1 fusion forms, including the common p210 (e13/e14a2) and p190 (e1a2) forms, as well as other rare fusion forms
This test is not useful for therapeutic monitoring of patients with a known BCR::ABL1 fusion form.
Testing Algorithm
For more information see:
-Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation
-Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation
CPT Code Information
81206
81207
81208
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| BADX | BCR/ABL1, RNA-Qual, Diagnostic | 55135-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 39466 | Diagnostic BCR/ABL1 Result | No LOINC Needed |
| MP001 | Specimen Type | 31208-2 |
| 19783 | Interpretation | 69047-9 |
Method Description
Total RNA is extracted from the patient's blood or bone marrow at the time of diagnosis and messenger RNA (mRNA) is reverse transcribed into complementary DNA (cDNA). The cDNA is then subjected to polymerase chain reaction (PCR) using 4 separate multiplex reactions. A qualitative result, which will include the relative ratio of target translocation mRNA to control GUSB gene mRNA, will be provided. Although this method employs a quantitative PCR platform, the results can be used to evaluate the relative expression levels of the translocation mRNA relative to control mRNA, thus, providing an improved measure of RNA quality in the assay. Reporting of results will be qualitative; either BCR::ABL1 mRNA positive/detected (with transcript type) or negative/not detected.(Unpublished Mayo method)
Forms
1. Hematopathology Patient Information (T676)
2. If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.